How much revenue does Sichuan Biokin Pharmaceutical make?

Sichuan Biokin Pharmaceutical reported 5.82 billion CNY in revenue for fiscal year 2024, up 936.3% from 561.87 million CNY in fiscal year 2023. In Q2 2025 revenue was 103.76 million CNY.

Where does Sichuan Biokin Pharmaceutical make most of its revenue?

Overseas: 85% of revenue by region in fiscal year 2021, followed by China (15%).

What companies are similar to Sichuan Biokin Pharmaceutical?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Jiangsu Hengrui Medicine Co., Ltd. (600276.SS), Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS), Junshi BIO (688180.SS), Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS).

Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SS) Stock

About Sichuan Biokin Pharmaceutical Co.,Ltd.

Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, manufacture, and sale of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 an...

At a glance

Sichuan Biokin Pharmaceutical reported revenue of 5.82 billion CNY for fiscal year 2024, up 936.3% from fiscal year 2023, and net income of 3.71 billion CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 103.76 million CNY, up 14.5% from a year before. Overseas was its largest region in fiscal year 2021, with 85% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.